Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results